Trial Profile
A phase III trial evaluating the efficacy and tolerability of liposomal cisplatin [Lipoplatin] + gemcitabine versus conventional cisplatin + gemcitabine as first-line therapy in patients with advanced non-small cell lung cancer.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Oct 2009
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- 24 Sep 2009 Interim results in 101 patients presented at ECCO/ESMO 2009.
- 20 Jun 2007 New trial record